Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. November 2025 06:00 ET | Quelle: Draig Therapeutics

Draig Therapeutics Appoints Seasoned Neuroscience Leader Ivana Magovčević-Liebisch as President and Chief Executive Officer

Dr Magovčević-Liebisch is an accomplished pharmaceutical and biotechnology executive with over 25 years of leadership experienceDr Ruth McKernan FMedSci CBE, co-founder and Interim CEO, will continue...
02. Oktober 2025 07:00 ET | Quelle: Draig Therapeutics

Draig Therapeutics Announces US FDA Clearance of IND Application for Phase 2 Study of DT-101 for the Treatment of Major Depressive Disorder

DT-101 is designed to allow effective modulation of the AMPA receptor without compromising safetyPhase 2 clinical trial initiation anticipated before the end of 2025Trial builds on positive Phase 1...
15. Juli 2025 04:00 ET | Quelle: Draig Therapeutics

Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors

Strong track record at executive and board level of building company value across all stages of development including supporting the development of multiple blockbuster medicines Cardiff, United...
18. Juni 2025 00:00 ET | Quelle: Draig Therapeutics

Draig Therapeutics Launches with $140 Million (£107 Million) Total Investment to Advance its Portfolio of Next-Generation Therapies for Major Neuropsychiatric Disorders

Clinical-stage company led by world-class team targeting core neurotransmission pathways underlying neuropsychiatric disorders with a rich pipeline of novel, potentially transformative...